Fachklinik Hornheide e.V. — Clinical Trial Site

10 Registered trials

3 Currently recruiting

Organisation

Fachklinik Hornheide e.V.

Location

Muenster, Germany

Identifier

ORG-100048787

Address

Dorbaumstrasse 300, Handorf, 48157, Germany

Departments

Department for Dermatology
Department of Dermatology
Dermatologie
Dermatology
Hauttumorzentrum
Internistische Onkologie
N/A
Oncology

Clinical trials at this site (10)

Search interface

A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancers Recruiting

2025-522402-21-00 Advanced solid tumors (cutaneous melanoma, mucosal mela 1 2026-03-27
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10… Recruiting

2024-512659-19-00 Advanced Melanoma 10 2025-03-31
A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARI… Recruiting

2024-511404-17-00 Unresectable or metastatic NRAS mutant cutaneous melano 5 2024-10-07
A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com… Ended

2022-501576-25-00 Melanoma 5 2023-07-07
Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U… Ended

2023-505772-30-00 Melanoma 5 2022-11-09
The STARBOARD Study: Phase 3 Study of Encorafenib and Binimetinib Plus Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresec… Ended

2024-512038-13-00 Metastatic or unresectable locally advanced BRAF V600E/ 5 2021-09-16
Adjuvant nivolumab treatment in stage II high-risk melanoma – A randomized, controlled, phase III trial with biomarker-based risk stratifica… Ended

2023-509394-23-00 Stage II melanoma arising from a primary cutaneous site 5 2020-06-12
A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-… Ended

2023-506881-30-00 Melanoma 3 2024-05-15
Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed … Ended

2023-509471-17-00 Metastatic or unresectable locally advanced BRAF V600E/ 4 2023-05-24
Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned… Ended

2025-520468-16-00 Cutaneous Melanoma, Relapsed/Refractory, Locally Advanc 4